bowel dysfunction

Dextran sulfate sodium salt (MW 4500-5500) is an anhydrous glucose polymer with a molecular weight range of 4500-5500. Dextran sulfate sodium salt (MW 4500-5500) inhibits human immunodeficiency virus replication by preventing viral adsorption to host cells. Dextran sulfate sodium salt (MW 4500-5500) is a commonly used modeling compound for inflammatory bowel disease. It can destroy the integrity of the intestinal mucosal barrier through the high negative charge caused by sulfate groups, leading to intestinal barrier damage, macrophage dysfunction, and bacterial flora disorder.

CU06-1004 (Sac-1004) is an orally active compound that acts as an endothelial dysfunction blocker. It mitigates endothelial dysfunction by inhibiting hyperpermeability and inflammation. The compound demonstrates efficacy in reducing vascular leakage and inflammation across multiple animal models, including those for diabetic retinopathy, stroke, cancer, and inflammatory bowel disease. Additionally, CU06-1004 improves conditions in a CDAA-induced mouse model of NASH and enhances cardiac function [1] [2] [3].

Propantheline bromide (Pro-Banthine) competitively antagonizes acetylcholine activity mediated by muscarinic receptors at neuroeffector sites on smooth muscle and exocrine gland cells. Propantheline Bromide is the bromide salt form of propantheline, a quaternary ammonium compound structurally related to belladonna alkaloids. An aspartic acid residue present in the N-terminal portion of the third transmembrane helix of the muscarinic receptor is believed to form an ionic bond with the tertiary or quaternary nitrogen of the antagonist. Antagonism leads to a reduction of exocrine glands secretions and to relax the bronchial muscle and reduce tone and motility of intestinal smooth muscle.

Bevenopran (CB-5945) is a peripheral antagonist of μ-opioid receptor and can be used in studies about the treatment of opioid-induced bowel dysfunction.

Axelopran sulfate is used in Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.